

Statements ^[1]

Find information and the latest updates and background information on recent events related to a few of our key products.

Featured image:



Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

[Read More](#) ^[2]

Novartis joins the Accelerating COVID-19 Therapeutic

Interventions and Vaccines (ACTIV) initiative

[Read More](#) [3]

Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide

[Learn More](#) [4]

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial

[Learn More](#) [5]

Novartis is making a strong contribution to the fight against the COVID-19 pandemic

[Read More](#) [6]

Novartis US response to COVID-19

[Read More](#) [7]

Corrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US

[Read More](#) [8]

Novartis provides update on use and safety of Beovu® in patients with wet AMD

[Read More](#) [9]

Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

[Read More](#) [10]

Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement

[Read More](#) [11]

Novartis statement on Zolgensma

[Read More](#) [12]

The Novartis comment letter submitted July 16, 2018 to the Department of Health and Human Services (HHS) in response to the “HHS Blueprint to Lower Drug Prices and Reduce out-of-Pocket-Costs.”

[Novartis response to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs](#) [13]

Novartis Pharmaceuticals Corporation (Novartis) Statement on Recall Outside the United States of Sandoz Generic Valsartan and Sandoz Valsartan and Hydrochlorothiazide Film-Coated Tablets

[Read More](#) [14]

Hero title:

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial

Accordion Type:

Collapsible

Source URL: <https://www.novartis.us/news/statements>

Links

[1] <https://www.novartis.us/news/statements>

[2] <https://www.novartis.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients>

[3] <https://www.novartis.us/news/statements/novartis-joins-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ>

[4] <https://www.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide>

[5] <https://www.us.sandoz.com/news/media-releases/novartis-donates-20000-doses-hydroxychloroquine-covid-19-pep-clinical-trial>

[6] <https://www.sandoz.com/news/media-releases/novartis-donation-consignment-30-million-hydroxychloroquine-tablets-ships-us>

[7] <https://www.novartis.us/news/statements/novartis-us-response-covid-19>

[8] <https://www.novartis.us/news/statements/corrective-action-certain-100-mg-sandimmune-and-neoral-blister-packages-us>

[9] <https://www.novartis.us/news/novartis-provides-update-use-and-safety-beovu-patients-wet-and>

[10] <https://www.us.sandoz.com/news/media-releases/sandoz-resolves-generic-drug-antitrust-investigation-us-0>

[11] <https://www.novartis.us/news/form-483-posting-us-food-and-drug-administration-fda-novartis-statement-0>

[12] <https://www.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy>

[13]

<https://www.novartis.us/sites/www.pharma.us.novartis.com/files/Novartis%20response%20to%20HHS%20RFI%20fi>

[14] <https://www.novartis.us/news/novartis-pharmaceuticals-corporation-novartis-statement-recall-outside-united-states-sandoz>